Hellerup, Denmark, 17 March 2022 – UNION therapeutics A/S (“UNION”), a privately held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious diseases, announces the full year results for the period 1 January to 31 December 2021.    

2021 has been a year of great progress for UNION with significant advancement to the clinical pipeline by successful development of the two lead molecules, orismilast and niclosamide, with the overall aim to develop best-in-class and first-in-class treatments within immunological and infectious diseases.

UNION has expanded the international collaborations for both orismilast and niclosamide. For orismilast UNION has entered a strategic collaboration and licensing agreement with Innovent Biologics for the development and commercialization of orismilast in Greater China. This agreement is a validation of the first-in-class and best-in-class potential of orismilast and expands UNION’s global footprint. For niclosamide, UNION has entered a collaboration with the University of Cambridge who have selected the niclosamide nasal spray for the Phase 2/3 platform trial PROTECT-V. This is a strong validation of the potential of the niclosamide nasal spray to protect immunocompromised patients from contracting COVID-19.

Moreover, the UNION organization has been significantly strengthened in 2021 with key hires across all levels of the organization. The UNION team has successfully executed on UNION’s overall strategy to match molecules and diseases in indications with high unmet medical need, and where UNION can maximize the potential of molecules through a combination of pharmaceutical innovation and strong clinical development capabilities.

Kim Kjøller, Chief Executive Officer of UNION therapeutics said:

2021 has been a year of great progress for UNION with accomplishment of a number of significant milestones. With advancements of our clinical programs with the lead molecules orismilast and niclosamide, expansion of our international collaborations and significant strengthening of the organization across all levels, UNION has established momentum and shown that across our clinical pipeline and strong team, we are set for the future of building a lasting Danish pharmaceutical company.”

Morten Boesen, Chief Financial Officer of UNION therapeutics adds:

“The achievements in 2021 have significantly contributed to our ambition of having a high-potential, diversified development portfolio, and positioned us well for reaching a number of important value inflection points in the coming period. We are very happy to see that our pipeline and strategy have been well received also by investors and collaborators, all of which has been instrumental in the maturing of the company we have seen throughout the year.” 

Financial result for the full year 2021

Highlights for orismilast

Highlights for niclosamide

Business highlights

UNION’s Annual Report for 2021

This announcement is a summary of UNION’s Annual Report for 2021, published on March 17, 2022. A PDF version of the Annual Report will be available for download here: annualreport2021

Management statement

The Board of Directors and Executive Management have approved the Annual Report 2021 of UNION, including the audited consolidated financial statements. The consolidated financial statements in the Annual Report 2021 have been prepared in accordance with International Financial Reporting Standards (IFRS).


Morten Boesen, Chief Financial Officer, UNION therapeutics A/S

+45 2381 5487

[email protected]

Media enquiries

Sarah Toft-Jørgensen, Director of Communications and IR, UNION therapeutics A/S

+45 5385 3044

[email protected]

About UNION therapeutics

UNION therapeutics is a privately held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious diseases. The company is currently working with two complementary chemistry classes, spanning immunology and microbiology with multiple candidates in clinical development. UNION is headquartered in Hellerup, Denmark, and led by an international team combining biotech entrepreneurs and seasoned pharma executives, with a track record of developing and launching more than fifteen marketed drugs. Read more at http://www.uniontherapeutics.com